ArticleMalaria journal2026
In vitro activity of the antimalarial, antibiotic drugs fosmidomycin and clindamycin against clinical isolates of bacterial bloodstream infections in febrile, hospitalized Ghanaian children.
Article in Malaria journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical and laboratory distinction between malaria and bacterial blood stream infections in patients with undifferentiated fever remains challenging. Misclassification may result in ineffective treatment with the risk of progression of disease and subsequent morbidity and mortality. A pragmatic solution is the use of multi-disease treatments effective against both malaria and the clinically most relevant bacterial pathogens. Fosmidomycin and clindamycin are two antibiotics that have demonstrated high efficacy in treating malaria. A multi-drug combination treatment of fosmidomycin, clindamycin, and artesunate has been evaluated for the treatment of malaria. To further explore whether fosmidomycin and clindamycin could be used in combined anti-malarial, anti-bacterial broad-spectrum chemotherapeutic treatment, the in vitro anti-bacterial activity of fosmidomycin and clindamycin was assessed against clinically relevant bacterial pathogens responsible for blood stream infections in sub-Saharan African children.
methodsIn vitro drug susceptibility testing was performed using clinical isolates of bacterial bloodstream infections from febrile, hospitalized children in Ghana. Isolates included the most common bacteria responsible for bloodstream infections in sub-Saharan African children, comprising Klebsiella pneumoniae, Escherichia coli, Streptococcus pneumoniae, Staphylococcus aureus, and non-typhoidal Salmonella (NTS). Minimum Inhibitory Concentrations of fosmidomycin and clindamycin were determined using the agar dilution method.
resultsThe findings of in vitro antimicrobial susceptibility testing demonstrated that all tested strains showed susceptibility to at least one of the antibiotics tested. Gram-negative strains demonstrated susceptibility to fosmidomycin (100%) but resistance to clindamycin, while gram-positive strains showed the opposite pattern: susceptibility to clindamycin (100%) but resistance to fosmidomycin.
conclusionsThe results underscore the potential of combining fosmidomycin and clindamycin in antimalarial treatment regimens as a multi-disease treatment strategy, particularly for febrile children. Such an approach would target both Plasmodium falciparum and the clinically most relevant bacterial pathogens, addressing one of the most important diagnostic and treatment challenges faced in malaria-endemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.